LSL Pharma Group Inc. (TSXV:LSL)

LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 23, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	45	47	40	-	-	-
Market Cap Growth	-11.58%	18.48%	-	-	-	-
Enterprise Value	69	61	54	-	-	-
Last Close Price	0.38	0.41	0.48	-	-	-
PE Ratio	12.14	14.28	-	-	-	-
PS Ratio	1.96	2.67	3.99	-	-	-
PB Ratio	1.86	1.90	4.62	-	-	-
P/TBV Ratio	4.34	4.13	-	-	-	-
EV/Sales Ratio	2.95	3.45	5.37	-	-	-
EV/EBITDA Ratio	22.03	35.92	-	-	-	-
EV/EBIT Ratio	62.01	150.86	-	-	-	-
Debt / Equity Ratio	1.15	0.87	1.88	2.84	1.15	1.02
Debt / EBITDA Ratio	9.03	11.30	-	-	47.86	4.08
Asset Turnover	0.47	0.42	0.35	0.29	0.31	-
Inventory Turnover	1.86	1.88	2.37	2.92	2.19	-
Quick Ratio	0.56	0.54	0.18	0.09	0.29	0.35
Current Ratio	1.28	1.59	0.48	0.38	0.89	0.52
Return on Equity (ROE)	16.27%	19.78%	-121.50%	-98.29%	-16.56%	-
Return on Assets (ROA)	1.40%	0.60%	-8.84%	-14.99%	-1.57%	-
Return on Capital (ROIC)	1.61%	0.71%	-11.37%	-19.12%	-1.98%	-
Return on Capital Employed (ROCE)	2.50%	0.90%	-	-	-	11.50%
Earnings Yield	7.85%	7.00%	-21.19%	-	-	-
FCF Yield	0.94%	-6.86%	-19.32%	-	-	-
Buyback Yield / Dilution	-30.07%	-31.18%	-20.94%	-11.78%	-8.34%	-14.88%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.